Prasad’s downfall signals a shift to libertarian regulation: The challenge for industry and patients is to couple misplaced enthusiasm for right-to-try with science-based approaches to generating evidence. A Perspective from @BioCentury's @steveusdin1:

Prasad's ouster from @US_FDA raises prospect of CBER reset: Uncertainty fueled by ideology, politics is increasing, but when dust settles industry and advocates may be happier, says @steveusdin1 in @BioCentury:

Sunday's deal between @GSK and Hengrui for up to 12 assets is 1 of the clearest signs yet that cross-border, East-West deals have been undergoing a foundational shift. @BioPharmaJosh and I take a look at why this deal is so important in @BioCentury:

Leads Biolabs' offering is the 16th biotech IPO on an East Asian exchange this year, 9 of which have been on the HKSE. 7 of those nine have come since mid-April. That compares with 11 biotech IPOs on NASDAQ in 2025.

Always knew Ozzy had a sweet tooth but thought it was for the leaf. h/t @BioBonanos

First clinical evidence spurs @sanofi takeout of @Medicxi best in class vax play Vicebio for $1.15B up front. via @BioBonanos:

A leaked memo on @IAmBiotech strategy is energizing anti-vaxxers, writes @BioCentury's @steveusdin1. Document describes BIO's investment in pro-vaccine communications, plans to engage with conservatives in and outside the Trump administration

RT @bio_clouseau: hmm the possible next head of CDER. A marketing and management degree vs the acting head dr corrigan-coray .

Amarin, Merck alum Karim Mikhail emerges as possible head of @US_FDA’s CDER, reports @BioCentury's @steveusdin1.

RT @DiBonaNFL: 🚨 NOLAN SMITH AUTO GIVEAWAY! 🚨. I’m giving away a Nolan Smith autographed rookie card following the launch of .

The biopharma industry is racing to counter the Trump MFN threat: With White House demanding 85% across-the-board drug price cuts, the biopharma industry hopes to avoid catastrophic policies via alternative concessions, writes @BioCentury's @steveusdin1

Setback for Stealth raises questions about @US_FDA’s implementation of rare disease policies. The biotech’s regulatory odyssey in Barth syndrome exemplifies the problems Makary has vowed to fix. via @SteveUsdin1 in @BioCentury

Looking for that special something to give your favorite @packers fan? Push here. #FlyEaglesFly

The biggest licensing deal yet for a China biotech asset -- @Pfizer taking rights to a 3SBio bispecific -- is also tied for 3rd largest biotech asset deal ever. The deal for a PD-(L)1 x VEGF has $PFE paying $1.25B u/f Here's @BioBonanos in @biocentury

RT @steveusdin1: FDA misses PDUFA goal for Stealth’s Barth syndrome treatment.It isn’t clear whether staffing cuts or loss of FDA champion….

Another missed deadline by RFK Jr. & Makary's @US_FDA -- this time for a treatment for a very rare disease:

Krause, @llborio on turmoil @US_FDA: "Moving the goalposts like this has a chilling effect on the entire biotech community and reduces appetite to develop critically needed new drugs and biologics in areas beyond just vaccines, including immunotherapies and cancer treatments.".

RT @steveusdin1: The leaked Trump administration 2026 HHS budget is sickening. If enacted, it will destroy American science. NIH budget sla….

RT @KevinH_PhD: After 21 years at my dream job, I’m very sad to announce my early retirement from the National Institutes of Health. My lif….

RT @PHLEaglesNation: Go Birds, @EmmittSmith22.